CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enhancing the solubility of therapeutic monoclonal antibodies (mAbs) using short RNA ligands. By designing these RNA molecules, the project aims to improve the stability and effectiveness of mAb formulations for various medical applications.
Usage of therapeutic monoclonal antibodies (mAbs) has over the past 20 years become one of the most powerful pharmacological strategies in the treatment of various types of cancer, cardiovascular diseases and autoimmune disorders.
Importantly, a central challenge in developing the required high protein concentration formulations of mAb therapeutics is the issue of protein solubility.
The current approaches for addressing this challenge typically involve using different osmolyte excipients such a…
UNIVERSITAT WIEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
